- Home
- LTRN vs MDCX Comparison
LTRN vs MDCX Comparison
Compare LTRN & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LTRN | MDCX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2M | 16.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LTRN | MDCX |
|---|---|---|
| Price | $3.22 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 272.4K | ★ 1.6M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.25 |
| 52 Week High | $5.74 | $8.39 |
Technical Indicators
Market Signals| Indicator | LTRN | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 68.65 | 40.12 |
| Support Level | $3.04 | $0.29 |
| Resistance Level | $3.79 | $0.36 |
| Average True Range (ATR) | 0.29 | 0.03 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 90.44 | 38.53 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.